Literature DB >> 27737324

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital.

Beatriz G Cavalheiro1, Leandro L Matos1, Ana Kober N Leite1, Marco Aurélio V Kulcsar1, Claudio R Cernea1, Lenine G Brandão1.   

Abstract

Objective: The aim of the present study was to describe the epidemiologic data, histological type, treatment and follow-up of the 811 patients treated for thyroid cancer in Instituto do Câncer do Estado de São Paulo (ICESP) over 5 years. Materials and methods: Retrospective analyses of electronic chart information.
Results: There were 679 cases (83.7%) of papillary thyroid cancer, 61 (7.5%) of follicular carcinoma, 54 (6.7%) of medullary carcinoma, 11 (1.4%) of poorly differentiated carcinoma and 6 of anaplastic carcinoma (0.7%). The majority of patients were female (82.2%), and the mean age was 50.5 ± 15 years. Two hundred forty-two patients had disease persistence or recurrence. At the last follow-up, 629 (77.6%) patients were alive and disease free, 141 (17.4%) were alive with disease, and 41 (5.1%) were deceased, with 37 deaths related to thyroid cancer.
Conclusion: This study was able to outline the profile, disease type and evolution of patients treated for thyroid cancer at a single tertiary hospital.

Entities:  

Year:  2016        PMID: 27737324     DOI: 10.1590/2359-3997000000209

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  3 in total

1.  Thyroid cancer overdiagnosis and overtreatment: a cross- sectional study at a thyroid cancer referral center in Ecuador.

Authors:  Paola Solis-Pazmino; Jorge Salazar-Vega; Eddy Lincango-Naranjo; Cristhian Garcia; Gabriela Jaramillo Koupermann; Esteban Ortiz-Prado; Tannya Ledesma; Tatiana Rojas; Benjamin Alvarado-Mafla; Cesar Carcamo; Oscar J Ponce; Juan P Brito
Journal:  BMC Cancer       Date:  2021-01-08       Impact factor: 4.430

2.  CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation.

Authors:  Yina Liao; Yijun Hua; Yizhuo Li; Changlin Zhang; Wendan Yu; Ping Guo; Kun Zou; Wenyang Li; Yao Sun; Ruozhu Wang; Yan Zuo; Silei Sui; Chunfang Tian; Jiaojiao Hao; Manyu Chen; Sheng Hu; Miao Chen; Qian Long; Xiaonan Wang; Lijuan Zou; Fangyun Xie; Wei Guo; Wuguo Deng
Journal:  Cell Death Differ       Date:  2020-11-08       Impact factor: 15.828

3.  Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling.

Authors:  Yina Liao; Yao Gao; An Chang; Zongjuan Li; Huayu Wang; Jing Cao; Wei Gu; Ranran Tang
Journal:  J Cell Mol Med       Date:  2020-09-15       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.